5-bromo-3-(N-methylpyrrolidin-3-yl)-1H-indole | 151680-85-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-bromo-3-(N-methylpyrrolidin-3-yl)-1H-indole
• 英文别名: 5-bromo-3-(1-methylpyrrolidin-3-yl)-1H-indole；5-bromo-3-(N-methylpyrrolidin-3-yl)1H-indole
• CAS: 151680-85-2
• 化学式: C₁₃H₁₅BrN₂
• 分子量: 279.18
• InChiKey: ZZQOVQIQWNYKBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-bromo-3-(N-methylpyrrolidin-3-yl)-1H-indole 在 四(三苯基膦)钯 sodium hydroxide 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 8.5h， 生成
  参考文献：
  名称：

  5-CYCLO INDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS

  摘要：

  公开号：

  EP0944595B1
• 作为产物：
  描述：

  N-甲基马来酰亚胺 在 lithium aluminium tetrahydride 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 27.0h， 生成 5-bromo-3-(N-methylpyrrolidin-3-yl)-1H-indole
  参考文献：
  名称：

  A Direct Synthesis of 3-(Pyrrolidin-3-yl)indoles for Use As Conformationally Restricted Analogs of Tryptamines

  摘要：

  本文描述了一种 3-(吡咯烷-3-基)吲哚 4 的高效两步合成法。吲哚与马来酰亚胺在回流乙酸中反应，生成 3-(吲哚-3-基)琥珀酰亚胺 6。反应时间和产量取决于吲哚 5 上的取代基。用 LAH 直接还原琥珀酰亚胺 6，可得到所需的构象受限的色胺衍生物 4。

  DOI：

  10.1055/s-1997-1214

文献信息

• 5-arylindole derivatives
  申请人：Pfizer Inc.

  公开号：US05994352A1

  公开（公告）日：1999-11-30

  Compounds of the formula ##STR1## wherein A, B, D, E, and F are each independently nitrogen or carbon; R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alkyl, --(CH.sub.2).sub.n R.sub.7, or C.sub.1 to C.sub.3 alkyl-aryl; R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen, cyano, nitro, --(CH.sub.2).sub.m NR.sub.8 R.sub.9, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.8 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 COR.sub.9, --(CH.sub.2).sub.m CONR.sub.7 R.sub.9, or --(CH.sub.2).sub.m CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, R.sub.4 and R.sub.5, and R.sub.5 and R.sub.6 may be taken together to form a five- to seven-membered alkyl ring, a six-membered ary ring, a five- to seven-membered heteroalkyl ring, having 1 heteroatom of N, O, or S, or a five- to six-membered heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R.sub.7 is --OR.sub.10, --SR0.sub.10, --SO.sub.2 NR.sub.10 R.sub.11, --NR.sub.10 SO.sub.2 R.sub.11, --NR.sub.10 CO.sub.2 R.sub.11, --NR.sub.10 COR.sub.11, --CONR.sub.10 R.sub.11, or --CO.sub.2 R.sub.10 ; R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, or C.sub.1 to C.sub.3 alkyl-aryl; m is 0, 1, or 2; n is 2, 3, or 4; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are each independently phenyl or substituted phenyl, wherein said substituted phenyl may be substituted with one to three of C.sub.1 to C.sub.4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, or C.sub.1 to C.sub.4 alkoxy, and the pharmaceutically acceptable salts thereof. These compounds are useful in treating migraine and other disorders and are new. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  式为##STR1##的化合物，其中A、B、D、E和F分别独立地为氮或碳；R.sub.1为氢、C.sub.1到C.sub.6烷基、--(CH.sub.2).sub.n R.sub.7，或C.sub.1到C.sub.3烷基-芳基；R.sub.2、R.sub.3、R.sub.4、R.sub.5和R.sub.6分别独立地为氢、C.sub.1到C.sub.6烷基、芳基、C.sub.1到C.sub.3烷基-芳基、卤素、氰基、硝基、--(CH.sub.2).sub.m NR.sub.8 R.sub.9、--(CH.sub.2).sub.m OR.sub.9、--SR.sub.9、--SO.sub.2 NR.sub.8 R.sub.9、--(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9、--(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9、--(CH.sub.2).sub.m NR.sub.8 COR.sub.9、--(CH.sub.2).sub.m CONR.sub.7 R.sub.9，或--(CH.sub.2).sub.m CO.sub.2 R.sub.9；R.sub.2和R.sub.3、R.sub.3和R.sub.4、R.sub.4和R.sub.5，以及R.sub.5和R.sub.6可以结合在一起形成五至七元烷基环、六元芳环、具有1个N、O或S杂原子的五至七元杂烷基环，或具有1个或2个N、O或S杂原子的五至六元杂芳基环；R.sub.7为--OR.sub.10、--SR0.sub.10、--SO.sub.2 NR.sub.10 R.sub.11、--NR.sub.10 SO.sub.2 R.sub.11、--NR.sub.10 CO.sub.2 R.sub.11、--NR.sub.10 COR.sub.11、--CONR.sub.10 R.sub.11，或--CO.sub.2 R.sub.10；R.sub.8、R.sub.9、R.sub.10和R.sub.11分别独立地为氢、C.sub.1到C.sub.6烷基，或C.sub.1到C.sub.3烷基-芳基；m为0、1或2；n为2、3或4；上述芳基和上述烷基-芳基的芳基基团分别独立地为苯基或取代苯基，其中所述取代苯基可以用C.sub.1到C.sub.4烷基、卤素、羟基、氰基、羧酰胺基、硝基，或C.sub.1到C.sub.4烷氧基取代，并且其药学上可接受的盐。这些化合物在治疗偏头痛和其他疾病方面是有用的，并且是新的。这些化合物是有用的精神治疗药物，是有效的5-羟色胺（5-HT.sub.1）激动剂，可用于治疗抑郁症、焦虑症、进食障碍、肥胖症、药物滥用、集群头痛、偏头痛、疼痛，以及与血管疾病相关的慢性阵发性半头痛和头痛等疾病，以及由于5-羟色胺神经传导不足而引起的其他疾病。这些化合物还可用作中枢作用降压药和扩血管药。
• [EN] INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN<br/>[FR] COMPOSÉS D'INDOLE ET PROCÉDÉS DE TRAITEMENT DE LA DOULEUR VISCÉRALE
  申请人：NEURAXON INC

  公开号：WO2009062319A1

  公开（公告）日：2009-05-22

  The invention features methods of treating visceral pain or a condition in a mammal caused by the action of nitric oxide synthase (NOS) or by the action of serotonin 5HT1D/1B receptors, by administering to a patient in need thereof a therapeutically effective amount of an indole compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. The methods of the invention may further comprise the administration of additional therapeutic agent. The invention also features new compounds of Formula (I), pharmaceutical compositions thereof, and methods of resolving enantiomeric mixtures.

  该发明涉及治疗哺乳动物体内因一氧化氮合酶（NOS）或5-羟色胺受体5HT1D/1B的作用引起的内脏疼痛或疾病的方法，通过向需要治疗的患者施用式(I)的吲哚化合物的治疗有效量，或其药学上可接受的盐或前药。该发明的方法还可以包括额外治疗剂的施用。该发明还涉及式(I)的新化合物、其药物组合物以及解决对映体混合物的方法。
• Thiophene-tryptamine derivatives
  申请人：Allelix Biopharmaceuticals Inc.

  公开号：US05770742A1

  公开（公告）日：1998-06-23

  5-Thiophene-substituted tryptamine analogs are provided, which exhibit selectivity towards 5-HT.sub.D1 receptors and consequently show potential in alleviation of the symptoms of migraine. The analogs are represented by the following general chemical formula: ##STR1## in which X represents H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 hydroxyalkyl or halogen, at the 4- or 5-position of the thiophene nucleus; Y represents a direct bond or a C.sub.1 -C.sub.3 alkylene group optionally substituted with hydroxyl: and Z represents amino, mono- or di-N-lower alkyl-substituted amino, or optionally N-lower alkyl-substituted pyrrolidine.

  提供了一种5-噻吩取代的色胺类似物，它们对5-HT.sub.D1受体表现出选择性，并因此显示出缓解偏头痛症状的潜力。这些类似物可以用以下一般化学式表示：##STR1## 其中X代表H、C.sub.1 -C.sub.4 烷基、C.sub.1 -C.sub.4 羟基烷基或卤素，位于噻吩核的4位或5位；Y代表直接键或可选择性地被羟基取代的C.sub.1 -C.sub.3 亚烷基；Z代表氨基、单或双-N-低级烷基取代的氨基，或可选择性地被N-低级烷基取代的吡咯烷。
• 5-cyclo indole compounds
  申请人：Allelix Biopharmaceuticals, Inc.

  公开号：US05998438A1

  公开（公告）日：1999-12-07

  Described herein are compounds selective for a 5-HT.sub.1D -like receptor, which have the general formula: ##STR1## wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO.sub.2 and N.sup.4 ; R.sup.1 is selected from H and OH; n is 0 or 1 as permited by chemical structure; R.sup.2 is selected from CR.sup.5 CR.sup.6 CH.sub.2 NR.sup.7 R.sup.8 or a group of formula II, III or IV: ##STR2## R.sup.3 is selected from H and benzoyl; R.sup.4 is selected from H, loweralkyl, benzyl, loweralkylcarbonyl, loweralkylaminocarbonyl, loweralkylaminothiocarbonyl, loweralkanoyl, loweralkylaminoimide and loweralkoxy-substituted loweralkylene; R.sup.5 and R.sup.6 are independently selected from H, loweralkoxy and hydroxy; R.sup.7 and R.sup.8 are independently selected from H and loweralkyl or R.sup.7 and R.sup.8 form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring; denotes a single or double bond; and R.sup.9, R.sup.10 and R.sup.11 are independently selected from H and loweralkyl. Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of a 5-HT.sub.1D -like receptor is implicated, such as migraine.

  本文描述的是对5-HT.sub.1D-类受体具有选择性的化合物，其具有以下通式：##STR1##其中A选自一个六元非芳香族、可选择性取代的碳环和一个六元非芳香族、可选择性取代的杂环，其中含有一个或两个来自O、S、SO、SO.sub.2和N.sup.4的杂原子；R.sup.1选自H和OH；n根据化学结构允许为0或1；R.sup.2选自CR.sup.5 CR.sup.6 CH.sub.2 NR.sup.7 R.sup.8或具有以下式II、III或IV的基团：##STR2##R.sup.3选自H和苯甲酰基；R.sup.4选自H、较低烷基、苄基、较低烷基羰基、较低烷基氨基羰基、较低烷基氨基硫氨基羰基、较低烷酰基、较低烷基氨基亚胺和较低烷氧基取代的较低烷基烯；R.sup.5和R.sup.6独立选自H、较低烷氧基和羟基；R.sup.7和R.sup.8独立选自H和较低烷基，或者R.sup.7和R.sup.8形成一个与它们附着的氮原子一起构成一个可选择性取代的3-至6-成员环的烷基桥；表示单键或双键；R.sup.9、R.sup.10和R.sup.11独立选自H和较低烷基。还描述了将这些化合物用作药物来治疗刺激5-HT.sub.1D-类受体所涉及的症状，如偏头痛。
• [EN] THIOPHENE- AND FURAN-TRYPTAMINE DERIVATIVES<br/>[FR] DERIVES DE LA THIOPHENETRYPTAMINE ET DE LA FURANETRYPTAMINE
  申请人：ALLELIX BIOPHARMACEUTICALS INC.

  公开号：WO1997043281A1

  公开（公告）日：1997-11-20

  (EN) 5-Substituted tryptamine compounds are provided, which exhibit selectivity towards 5-HTD1 receptors and consequently show potential in alleviation of the symptoms of migraine. The analogs are represented by general chemical formula (I) in which T represents an optionally substituted thiophene group of formula (a) bonded to the indole nucleus through its 2- or 3-position, or an optionally substituted furan group of formula (b) bonded to the indole nucleus through its 2- or 3-position; X represents H, C1-C4 alkyl, C1-C4 hydroxyalkyl or halogen, at the 4- or 5-position of the nucleus; Y represents a direct bond or a C1-C3 alkylene group optionally substituted with hydroxyl; and Z represents amino, mono- or di-N-lower alkyl-substituted amino, or an N-heterocyclic group selected from pyrrolidine, pyrroline, azetidine and piperidine, the N-heterocyclic group being optionally substituted with at least one substituent independently selected from lower alkyl, lower alkoxy-lower alkyl and hydroxy-lower alkyl.(FR) L'invention porte sur des composés de tryptamine substituée en 5 présentant une sélectivité vis-à-vis des récepteurs 5-HTD1 et de ce fait une capacité potentielle de soulagement de la migraine. Les analogues sont représentés par la formule générale (I) dans laquelle: T représente un groupe thiophène facultativement substitué de formule (a) lié au noyau d'indole par ses positions 2 et 3, ou un groupe furane facultativement substitué de formule (b) lié au noyau d'indole par ses positions 2 et 3; X représente H, C1-C4 alkyle, C1-C4 hydroxyalkyle ou halogène, en position 4 ou 5 du noyau; Y représente une liaison directe ou un groupe C1-C3 alkylène facultativement substitué par hydroxyle; et Z représente amino, amino substitué par un mono ou di N-alkyle inférieur, ou un groupe N-hétérocyclique choisi parmi pyrrolidine, pyrroline, azétidine et pipéridine, le groupe N-hétérocyclique pouvant être facultativement substitué par au moins un substituant choisi indépendamment parmi alkyle inférieur, alcoxy inférieur-alkyle inférieur et hydroxy-alkyle inférieur.

  提供了5-取代色胺类化合物，其对5-HTD1受体具有选择性，因此显示出在缓解偏头痛症状方面的潜力。这些类似物由一般化学式(I)表示，其中T代表公式(a)的可选取代噻吩基，通过其2-或3-位置与吲哚核相结合，或公式(b)的可选取代呋喃基，通过其2-或3-位置与吲哚核相结合；X代表核的4-或5-位置的H、C1-C4烷基、C1-C4羟基烷基或卤素；Y代表直接键或C1-C3烷基烯基，可选地取代羟基；Z代表氨基、单或双N-较低烷基取代的氨基，或从吡咯烷、吡咯烯、氮杂环戊烷和哌啶中选择的N-杂环基团，该N-杂环基团可选择地取代至少一个取代基，独立地选择自较低烷基、较低烷氧基-较低烷基和羟基-较低烷基。